Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JNJ-64264681 and Safimaltib in B-cell Malignancies
NCT04657224Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Feb 2021
- Primary completion
- Jan 2025
- Modality
- Small Molecules
- Countries
- 12
01
Overview
Phase 1, open-label trial of JNJ-64264681 and JNJ-67856633 in non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL) (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Dose-limiting Toxicity at 28 days and Adverse Events. Started Feb 2021; status: completed.
02
Drugs
JNJ-64264681JNJ-67856633
03
Conditions
non-Hodgkin lymphoma (NHL)chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT04657224.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04657224.